Boots UK Launches In-Store Weight Loss Drug Service
Analysis based on 8 articles · First reported Feb 13, 2026 · Last updated Feb 13, 2026
The launch of Walgreens Boots Alliance's in-store weight loss drug service is expected to positively impact Walgreens Boots Alliance by expanding its healthcare offerings and potentially increasing its market share. It also benefits Eli Lilly and Company and Novo Nordisk by making their weight loss treatments, Mounjaro and Wegovy, more accessible to consumers.
Walgreens Boots Alliance has launched a new in-store service for weight loss drugs, including Mounjaro (made by Eli Lilly and Company) and Wegovy (made by Novo Nordisk), across 17 stores in the United Kingdom. This trial service allows customers to have in-person consultations with a pharmacist and purchase these medications directly, a departure from the previous online-only or restricted United Kingdom — National Health Service prescription models. Jamie Kerruish, chief healthcare officer at Walgreens Boots Alliance, emphasized the convenience and comprehensive support offered by this new service, catering to individuals affected by obesity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard